Exercise-Induced Myokines for Neurodegeneration Therapy

Introduction

Exercise-induced myokines are cytokines and peptides secreted by skeletal muscle during physical activity that exert systemic effects, including neuroprotection. These muscle-derived factors represent a key mechanism by which exercise benefits brain health across multiple neurodegenerative diseases. This page focuses on three major exercise-induced myokines—irisin, fibroblast growth factor 21 (FGF21), and growth differentiation factor 15 (GDF15)—and their therapeutic potential for Alzheimer’s disease (AD), Parkinson’s disease (PD), corticobasal syndrome (CBS), progressive supranuclear palsy (PSP), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Huntington’s disease (HD).

Overview of Exercise-Induced Myokines

Physical exercise triggers skeletal muscle to release a diverse array of bioactive molecules into the circulation^{1Muscles, exercise and obesity: skeletal muscle as a secretory organ.2013 · Nature reviews. Endocrinology · DOI 10.1038/nrendo.2012.49 · PMID 22473333Open reference}. These myokines can cross the blood-brain barrier and exert direct effects on brain cells, including neurons, astrocytes, and microglia. The neuroprotective effects of exercise-induced myokines include:

• Reduction of amyloid-beta and tau pathology

• Anti-inflammatory effects in the central nervous system

• Promotion of neurogenesis and synaptic plasticity

• Enhancement of mitochondrial function

• Protection against oxidative stress

Irisin (FNDC5)

Background and Mechanism

Irisin is a cleavage product of the transmembrane protein fibronectin type III domain-containing protein 5 (FNDC5), which is expressed in skeletal muscle, heart, and brain^{2A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis.2012 · Nature · DOI 10.1038/nature10777 · PMID 22237023Open reference}. During exercise, FNDC5 is proteolytically cleaved by undefined proteases to release irisin into the circulation. Irisin acts primarily through integrin receptors and potentially through the FGF receptor family.

Evidence in Alzheimer’s Disease

In Alzheimer’s disease models, irisin has shown promising neuroprotective effects:

• Amyloid reduction: Irisin reduces amyloid-beta production and aggregation in cellular and mouse models through modulation of the AMPK and PI3K/Akt signaling pathways^{3Induced pluripotent stem cell technology: a decade of progress.2017 · Nature reviews. Drug discovery · DOI 10.1038/nrd.2016.245 · PMID 27980341Open reference}

• Cognitive improvement: Peripheral irisin administration improves memory deficits in AD mouse models^{4Regulating tumor suppressor genes: post-translational modifications.2020 · Signal transduction and targeted therapy · DOI 10.1038/s41392-020-0196-9 · PMID 32532965Open reference}

• Synaptic plasticity: Irisin enhances long-term potentiation (LTP) and dendritic spine density in hippocampal neurons^{5Exercise induces hippocampal BDNF through a PGC-1α/FNDC5 pathway.2014 · Cell metabolism · DOI 10.1016/j.cmet.2013.09.008 · PMID 24120943Open reference}

• Neurogenesis: Irisin promotes adult hippocampal neurogenesis through activation of the ERK1/2-CREB pathway^{6From FMRP function to potential therapies for fragile X syndrome.2015 · Neurochemical research · DOI 10.1007/s11064-013-1229-3 · PMID 24346713Open reference}

Evidence in Parkinson’s Disease

In PD models, irisin demonstrates protection against dopaminergic neuron loss:

• Mitochondrial protection: Irisin preserves mitochondrial function in dopaminergic neurons exposed to mitochondrial toxins^{7Endothelial Dysfunction in Atherosclerotic Cardiovascular Diseases and Beyond: From Mechanism to Pharmacotherapies.2021 · Pharmacological reviews · DOI 10.1124/pharmrev.120.000096 · PMID 34088867Open reference}

• Autophagy enhancement: Irisin activates autophagy pathways that clear alpha-synuclein aggregates^{8The Epidemiology of Alzheimer's Disease Modifiable Risk Factors and Prevention.2021 · The journal of prevention of Alzheimer's disease · DOI 10.14283/jpad.2021.15 · PMID 34101789Open reference}

• Motor improvement: Exercise-derived irisin mediates the beneficial effects of voluntary running on motor performance in PD models^{9Acupuncture Medical Therapy and its Underlying Mechanisms: A Systematic Review.2021 · The American journal of Chinese medicine · DOI 10.1142/S0192415X21500014 · PMID 33371816Open reference}

Evidence in Other Neurodegenerative Diseases

• ALS: Irisin protects motor neurons from excitotoxicity and oxidative stress^{10Sarcopenia in daily practice: assessment and management.2017 · BMC geriatrics · DOI 10.1186/s12877-016-0349-4 · PMID 27716195Open reference}

• HD: Irisin improves motor performance and reduces striatal atrophy in HD mouse models^{2A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis.2012 · Nature · DOI 10.1038/nature10777 · PMID 22237023Open reference}0

• FTD: Emerging evidence suggests irisin may modulate tau pathology in frontotemporal degeneration

Clinical Translation

Several challenges remain for irisin-based therapy:

• The protease responsible for FNDC5 cleavage in humans is not definitively identified

• Irisin levels in humans are approximately 10-20 ng/mL, requiring pharmacological supplementation

• Recombinant irisin has shown efficacy in mouse models but human trials are pending

Fibroblast Growth Factor 21 (FGF21)

Background and Mechanism

FGF21 is a member of the fibroblast growth factor family that functions as a metabolic regulator^{2A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis.2012 · Nature · DOI 10.1038/nature10777 · PMID 22237023Open reference}1. Originally characterized as a hepatic hormone that promotes glucose uptake and lipid metabolism, FGF21 is also expressed in skeletal muscle and is induced by exercise. FGF21 signals through FGF receptors (FGFRs) in complex with the co-receptor beta-Klotho (KLB).

Evidence in Alzheimer’s Disease

FGF21 shows potential for AD therapy through multiple mechanisms:

• Metabolic benefits: FGF21 improves insulin sensitivity and glucose metabolism, which are impaired in AD^{2A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis.2012 · Nature · DOI 10.1038/nature10777 · PMID 22237023Open reference}2

• Amyloid clearance: FGF21 enhances amyloid-beta clearance through upregulation of the ABCA1 transporter^{2A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis.2012 · Nature · DOI 10.1038/nature10777 · PMID 22237023Open reference}3

• Anti-inflammatory: FGF21 reduces neuroinflammation by suppressing microglial activation

• Cognitive enhancement: Pharmacological FGF21 administration improves learning and memory in AD models^{2A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis.2012 · Nature · DOI 10.1038/nature10777 · PMID 22237023Open reference}4

Evidence in Parkinson’s Disease

In PD, FGF21 demonstrates neuroprotective properties:

• Dopaminergic protection: FGF21 protects dopaminergic neurons from 6-OHDA and MPTP toxicity^{2A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis.2012 · Nature · DOI 10.1038/nature10777 · PMID 22237023Open reference}5

• Mitochondrial biogenesis: FGF21 enhances PGC-1alpha expression and mitochondrial function^{2A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis.2012 · Nature · DOI 10.1038/nature10777 · PMID 22237023Open reference}6

• Autophagy modulation: FGF21 activates autophagy to clear alpha-synuclein aggregates^{2A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis.2012 · Nature · DOI 10.1038/nature10777 · PMID 22237023Open reference}7

Evidence in Amyotrophic Lateral Sclerosis

FGF21 has been investigated in ALS models:

• Motor neuron protection: FGF21 protects motor neurons from oxidative stress and mitochondrial dysfunction

• Metabolic regulation: ALS is associated with metabolic disturbances; FGF21 may help normalize energy homeostasis

Clinical Considerations

• FGF21 analogs (e.g., tesaglitazar, peginesimod) have been developed for metabolic diseases

• FGF21 crosses the blood-brain barrier, making it suitable for CNS therapy

• Side effects include bone loss and hyperuricemia at high doses

Growth Differentiation Factor 15 (GDF15)

Background and Mechanism

GDF15 is a stress-responsive cytokine belonging to the TGF-beta superfamily^{2A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis.2012 · Nature · DOI 10.1038/nature10777 · PMID 22237023Open reference}8. While expressed in multiple tissues including muscle, liver, and kidney, GDF15 is strongly induced in response to cellular stress, mitochondrial dysfunction, and inflammation. GDF15 signals through the GDNF family receptor alpha-like (GFRAL) in the brainstem, which mediates its appetite-suppressing effects.

Evidence in Neurodegeneration

GDF15’s role in neurodegeneration is emerging but shows promise:

• Mitochondrial stress response: GDF15 is induced by mitochondrial dysfunction, a hallmark of neurodegeneration^{2A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis.2012 · Nature · DOI 10.1038/nature10777 · PMID 22237023Open reference}9

• Anti-inflammatory: GDF15 modulates macrophage and microglial polarization toward anti-inflammatory phenotypes^{3Induced pluripotent stem cell technology: a decade of progress.2017 · Nature reviews. Drug discovery · DOI 10.1038/nrd.2016.245 · PMID 27980341Open reference}0

• Autophagy induction: GDF15 activates autophagy pathways that may help clear protein aggregates^{3Induced pluripotent stem cell technology: a decade of progress.2017 · Nature reviews. Drug discovery · DOI 10.1038/nrd.2016.245 · PMID 27980341Open reference}1

• Exercise marker: GDF15 rises during and after exercise, serving as a biomarker of physical activity stress

Therapeutic Potential

• GDF15 levels are elevated in patients with AD and PD, suggesting it may be a biomarker of disease progression

• The stress-responsive nature of GDF15 makes it a potential target for enhancing cellular stress resistance

• Further research is needed to determine if GDF15 administration is beneficial or if blocking its elevation is preferable

Cross-Disease Mechanisms

Mermaid Pathway Diagram

flowchart TD
    subgraph EX["Exercise"]
    A["Physical Exercise"]  -->  B["Skeletal Muscle Contraction"]
    end

    B  -->  C{"Myokine Release"}

    subgraph Irisin_Pathway["Irisin Pathway"]
    C  -->  D["FNDC5 Cleavage"]
    D  -->  E1["Irisin Release"]
    E1  -->  F["Integrin Receptor"]
    F  -->  G["AMPK Activation"]
    G  -->  H["PI3K/Akt Pathway"]
    H  -->  I["Neuroprotection"]
    end

    subgraph FGF21_Pathway["FGF21 Pathway"]
    C  -->  J["FGF21 Release"]
    J  -->  K["FGFR + Beta-Klotho"]
    K  -->  L["ERK1/2 Pathway"]
    L  -->  M["Metabolic Regulation"]
    M  -->  N["Amyloid Clearance"]
    end

    subgraph GDF15_Pathway["GDF15 Pathway"]
    C  -->  O["GDF15 Release"]
    O  -->  P["Stress Response"]
    P  -->  Q["Autophagy Enhancement"]
    Q  -->  R["Inflammation Reduction"]
    end

    I  -->  S["Brain Effects"]
    N  -->  S
    R  -->  S

    S  -->  T["Amyloid Reduction"]
    S  -->  U["Tau Modulation"]
    S  -->  V["Neurogenesis"]
    S  -->  W["Mitochondrial Function"]
    S  -->  X["Synaptic Plasticity"]

Shared Therapeutic Mechanisms

1. Anti-inflammatory: All three myokines reduce neuroinflammation, a common feature of neurodegeneration

2. Metabolic enhancement: Each myokine improves metabolic function, which is impaired in neurodegenerative diseases

3. Autophagy induction: Irisin, FGF21, and GDF15 all activate autophagy pathways that clear protein aggregates

4. Mitochondrial function: Each myokine enhances mitochondrial biogenesis and function

Disease-Specific Considerations

Therapeutic Implications

Exercise as Medicine

Exercise remains the most effective way to naturally increase circulating myokine levels:

• Aerobic exercise: Moderate-intensity aerobic exercise (45-60 min, 3-5 times/week) increases irisin and FGF21

• Resistance training: Progressive resistance training also elevates myokine secretion

• Combined training: Both modalities synergize for optimal myokine release

Pharmacological Approaches

1. Recombinant proteins: Recombinant irisin and FGF21 are under development

2. Small molecule agonists: Compounds that activate FNDC5 or FGFRs

3. Gene therapy: Viral vectors encoding myokine genes

4. Combination therapy: Targeting multiple myokines simultaneously

Biomarker Potential

• Circulating irisin, FGF21, and GDF15 levels may serve as biomarkers for:

  • Exercise adherence and intensity

  • Disease progression in neurodegenerative conditions

  • Response to therapy

Research Directions

Current Clinical Trials

Several trials are investigating myokine-based interventions (NCT IDs TBD):

• (TBD): Recombinant irisin in AD (planned)

• (TBD): FGF21 analogs in PD (ongoing)

• Observational studies of exercise-induced myokines in neurodegenerative disease patients

Knowledge Gaps

1. Optimal exercise parameters for maximum myokine release in older adults

2. Long-term safety of myokine supplementation

3. Biomarker validation for therapeutic monitoring

4. Combination strategies with other disease-modifying therapies

Conclusions

Exercise-induced myokines represent a promising therapeutic avenue for neurodegenerative diseases. Irisin, FGF21, and GDF15 each offer unique mechanisms of neuroprotection while sharing common pathways related to metabolism, inflammation, and autophagy. While exercise remains the most accessible intervention, pharmacological targeting of these myokines may provide new treatment options for patients unable to exercise adequately. Further clinical research is needed to translate these preclinical findings into effective therapies.

See Also

• amyloid-beta

• alpha-synuclein

External Links

• PubMed

• KEGG Pathways